These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

69 related articles for article (PubMed ID: 34703233)

  • 1. Erratum: An Evidence-Based Review of OLZ/SAM for Treatment of Adults with Schizophrenia or Bipolar I Disorder [Corrigendum].
    Neuropsychiatr Dis Treat; 2021; 17():3135-3136. PubMed ID: 34703233
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combination of olanzapine and samidorphan has no clinically relevant effects on ECG parameters, including the QTc interval: Results from a phase 1 QT/QTc study.
    Sun L; Yagoda S; Xue H; Brown R; Nangia N; McDonnell D; Rege B; von Moltke L; Darpo B
    Prog Neuropsychopharmacol Biol Psychiatry; 2020 Jun; 100():109881. PubMed ID: 32004636
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Erratum: Bipolar Spectrum Disorders And Associated Factors Among Adults Attending An Antiretroviral Therapy Clinic In Gedeo Zone Health Centers, Southern Ethiopia [Corrigendum].
    Neuropsychiatr Dis Treat; 2019; 15():2907. PubMed ID: 31632039
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combination of Olanzapine and Samidorphan Has No Clinically Significant Effect on the Pharmacokinetics of Lithium or Valproate.
    Sun L; Yagoda S; Yao B; Graham C; von Moltke L
    Clin Drug Investig; 2020 Jan; 40(1):55-64. PubMed ID: 31584140
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and Safety of a Combination of Olanzapine and Samidorphan in Adult Patients With an Acute Exacerbation of Schizophrenia: Outcomes From the Randomized, Phase 3 ENLIGHTEN-1 Study.
    Potkin SG; Kunovac J; Silverman BL; Simmons A; Jiang Y; DiPetrillo L; McDonnell D
    J Clin Psychiatry; 2020 Mar; 81(2):. PubMed ID: 32141723
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Erratum: Safety and Tolerability of Cariprazine in Patients with Schizophrenia: A Pooled Analysis of Eight Phase II/III Studies [Corrigendum].
    Neuropsychiatr Dis Treat; 2021; 17():1481. PubMed ID: 34040374
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Erratum: Neural Correlates of Cognitive Dysfunction in Conditional Reasoning in Schizophrenia: An Event-Related Potential Study [Corrigendum].
    Neuropsychiatr Dis Treat; 2024; 20():835-836. PubMed ID: 38601068
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A randomized, double-blind, placebo-controlled proof of concept study to evaluate samidorphan in the prevention of olanzapine-induced weight gain in healthy volunteers.
    Silverman BL; Martin W; Memisoglu A; DiPetrillo L; Correll CU; Kane JM
    Schizophr Res; 2018 May; 195():245-251. PubMed ID: 29158012
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Erratum: Motor Functional Characteristics in Attention-Deficit/Hyperactivity Disorder and Autism Spectrum Disorders: A Systematic Review [Corrigendum].
    Neuropsychiatr Dis Treat; 2022; 18():1799-1800. PubMed ID: 36039159
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Erratum: Evaluation of
    Neuropsychiatr Dis Treat; 2022; 18():1271-1272. PubMed ID: 35784514
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Erratum: A Predictive Model Offor Attention Deficit Hyperactivity Disorder Based on Clinical Assessment Tools [Corrigendum].
    Neuropsychiatr Dis Treat; 2020; 16():1943. PubMed ID: 32982242
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Erratum: Gait and Balance Disorder in Patients with Transient Ischemic Attack or Minor Stroke [Corrigendum].
    Neuropsychiatr Dis Treat; 2022; 18():1269-1270. PubMed ID: 35784515
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Olanzapine Plus Samidorphan in Subjects with Schizophrenia and Comorbid Alcohol Use Disorder: Rationale and Design for a Phase II, Double-blind, Randomized Study.
    Citrome L; O'Malley SS; McDonnell D; Jiang Y; Simmons AC; Berry MP; Dipetrillo LE
    Innov Clin Neurosci; 2019 May; 16(5-6):15-21. PubMed ID: 31440397
    [No Abstract]   [Full Text] [Related]  

  • 14. A Phase I Open-Label Study to Evaluate the Effects of Rifampin on the Pharmacokinetics of Olanzapine and Samidorphan Administered in Combination in Healthy Human Subjects.
    Sun L; McDonnell D; Yu M; Kumar V; von Moltke L
    Clin Drug Investig; 2019 May; 39(5):477-484. PubMed ID: 30888624
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Erratum: Validation and Functional Relevance of the Short Form of the Perceived Deficits Questionnaire for Depression for Japanese Patients with Major Depressive Disorder [Corrigendum].
    Neuropsychiatr Dis Treat; 2024; 20():491-492. PubMed ID: 38463458
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Olanzapine Plus Samidorphan (ALKS 3831) in Schizophrenia and Comorbid Alcohol Use Disorder: A Phase 2, Randomized Clinical Trial.
    Brunette MF; Correll CU; O'Malley SS; McDonnell D; DiPetrillo L; Jiang Y; Simmons A; Silverman BL; Citrome L; Green AI
    J Clin Psychiatry; 2020 Mar; 81(2):. PubMed ID: 32160422
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Erratum: Current Perception Threshold Testing in Pharyngeal Paresthesia Patients with Depression or Anxiety [Corrigendum].
    Neuropsychiatr Dis Treat; 2020; 16():1145. PubMed ID: 32440129
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Erratum: Performance of the Arabic Population on the Adolescent-Adult Sensory Profile: An Observational Study [Corrigendum].
    Neuropsychiatr Dis Treat; 2020; 16():837. PubMed ID: 32280224
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Erratum: Serum miR-128 Serves as a Potential Diagnostic Biomarker for Alzheimer's Disease [Corrigendum].
    Neuropsychiatr Dis Treat; 2021; 17():513. PubMed ID: 33623385
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Erratum: Maternal and Paternal Depression During Pregnancy in China: Prevalence, Correlates, and Network Analysis [Corrigendum].
    Neuropsychiatr Dis Treat; 2021; 17():2527. PubMed ID: 34376981
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.